Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Terns Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing small-molecule drugs for oncology & metabolic diseases.
United States of America
TERN
Tevogen Bio Holdings Inc. Logo
Developing precision, off-the-shelf T cell therapies for cancer, infections, and neuro disorders.
United States of America
TVGN
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom
TCF
Theriva Biologics, Inc. Logo
Develops systemic oncolytic virus therapies to selectively destroy difficult-to-treat cancers.
United States of America
TOVX
Thirdeye Systems Ltd. Logo
Develops AI-driven thermal/visual perception solutions for defense, security & autonomous systems.
Israel
THES
TiumBio Co., Ltd. Logo
Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.
South Korea
321550
Tiziana Life Sciences Ltd Logo
Biotech firm developing immunotherapies for neurodegenerative diseases like MS and Alzheimer's.
United States of America
TLSA
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden
TOL
ToolGen Incorporated Logo
A biotech firm licensing genome editing patents for therapeutics and agriculture.
South Korea
199800
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.